Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Direct Meds vs Luma Health Co

Direct Meds
Graded #19

Higher grade

vs+7.599999999999994
Luma Health Co
Graded #59

Lower grade

The verdict

Direct Meds takes it — 82.6/100 to 75/100.

Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs offering an oral/sublingual route alongside injectable — semaglutide from ~$179 sublingual (~$297 injectable), tirzepatide ~$224/$399, with an intro promo near $147, all-inclusive and no membership.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueDirect Meds +16
85
69
Dose & formulationDirect Meds +19
88
69
Clinical oversightLuma Health Co +3
80
83
Labs & monitoringLuma Health Co +19
78
97
FulfillmentDirect Meds +10
80
70
Contract termsDirect Meds +25
80
55
Direct Meds · left barLuma Health Co · right bar

The numbers

MetricDirect MedsLuma Health Co
WeighScore82.6/10075/100
GradeB−C
Scorecard rank#19#59
Semaglutide$179/mo$120/mo (plus a separate fee, compounded)
Tirzepatide$224/mo$180/mo (compounded)
CoverageNot publicly listed30 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Direct Meds

Graded #19 · B−

Strengths

  • Rare oral/sublingual option in addition to injectable
  • All-inclusive pricing with no separate membership fee
  • Both molecules — semaglutide and tirzepatide
  • Intro promotional pricing near $147

Where it loses points

  • Compounded only — not FDA-approved
  • Pricing is company-stated, not independently live-verified
  • Newer and somewhat ambiguous (operates across multiple domains)
  • States served are not disclosed
Luma Health Co

Graded #59 · C

Strengths

  • Transparent, competitive pricing published up front — compounded semaglutide from $120/mo, tirzepatide from $180/mo, retatrutide from $170/mo
  • No subscription, monthly fee or membership — a direct-to-patient model where you pay per medication, and follow-up visits are free
  • Free initial consults for first responders, law enforcement, military, nurses and teachers ($0), and $25 for other healthcare workers
  • Founded and led by a named family nurse practitioner (Tiffani McKnight, FNP-C) licensed across 30 states/DC, with HIPAA-compliant virtual visits
  • HSA/FSA funds and financing accepted, with itemized invoices for HSA/FSA submission

Where it loses points

  • Offers compounded retatrutide (labeled "RTT/GLP-3"), an investigational triple agonist not FDA-approved — a higher-risk, less-studied option
  • Compounded medications only — no brand-name Wegovy, Zepbound or Ozempic — and compounded GLP-1s aren't FDA-reviewed or approved
  • No LegitScript certification shown and no compounding-pharmacy partner named, so the dispensing pharmacy can't be independently verified
  • Small, newly established founder-led practice with a thin website and limited public track record or third-party reviews
  • Medication prices are "starting at" and billed on top of a one-time consult fee, so the true first-month cost runs higher than the headline

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard